. Polyanion Competition Assay: dPG-NH2-miR-34a polyplex (N/P 9) was incubated in the presence of 0.1, 0.15, 0.17, 0.2, 0.22 and 0.25 IU of heparin. Solutions were mixed well, incubated for 15 minutes and then loaded into a 2% agarose gel and run for 30 minutes at 100 V. Free miRNA was run as a reference.
MRI analysis of our intracranial U-87 GBM model clearly shows extravasation of Gd-DTPA (Gadolinium diethylenetriamine pentaacetic acid), confirming the fact that the BBB is compromised in this GBM model ( Figure S4 ). Additional support for the BBB crossing by our polyplex is provided by the ex vivo image that shows Cy5 fluorescence in the tumor in the brain and not the rest of the healthy brain ( Figure 7B ). Furthermore, evidence of impaired BBB integrity was previously shown on the same U-87 MG model by a modified Miles assay using Evans Blue which binds in the circulation to albumin and extravasates from leaky vessels (Satchi-Fainaro et al., Cancer Cell 2005) . Figure S4 . MRI scans of a SCID mouse bearing a mCherry-labeled U-87 GBM intracranial tumor were performed using a 7 Tesla MRI (Bruker Biospec). For BBB integrity evaluations, images were collected before and following administration of the contrast medium Magnetol® (Gadolinium-DTPA (Gd-DTPA) 0.5 M, 0.1 mmol/kg) (Soreq Radiopharmaceuticals, Israel), as described below.
Supplementary data
All tissue culture reagents were purchased from Biological Industries Ltd (Beit Ha Emek, Israel), unless otherwise indicated. Chemical reagents, including salts and solvents, were purchased from Sigma-Aldrich Israel (Rehovot, Israel). Boyden chambers 8 m were from Transwell-Costar Corp. Hema 3 Stain System was from Fisher Diagnostics. EGM-2 medium was from Cambrex, USA and endothelial cells growth supplement (ECGS) from Zotal, Israel. 2-Iminothiolane was purchased from Sigma-Aldrich (Germany). Maleimide derivative of indodicarbocyanine (IDCC) dye was provided by mivenion GmbH. Sephadex G-25 Superfine was purchased from GE Healthcare (Germany). For buffers and sample preparations, ultrapure water (resistivity ~ 18 MΩ cm −1 , pH = 5.6 ± 0.2) was used. Sodium phosphate buffers (10 mM) and (50 mM, 5 mM EDTA) were used for the dye coupling reaction.
dPG-NH2 synthesis: Dendritic polyglycerol with average molecular weight of 10 kDa (PDI = 1.8) was prepared following literature procedures [40] . To convert 90% of all hydroxyl groups on dPG into amines, the hydroxyl groups were first activated using methanesulfonyl chloride. Mesyl groups were substituted by azides in a successive step. Finally, reduction of the azides by triphenylphosphine via Staudinger reduction resulted in formation of the desired amines. For optimal purification, extensive dialysis was carried out after each reaction step.
Quantification of functionalization degree was accomplished by 1 H NMR spectroscopy. 1 H NMR (300 MHz, CD3OD):  = 3.31-2.40 functionalized PG groups), 4.01-3.21 (PG); 13 C NMR (75 MHz, CD3OD): = 83.0-65.5 (PG), 55.5-43.6 functionalized PG groups).
Coupling of mal-IDCC dye to dPG-NH2 90%: 20 mg (2.2 µmol) of dPG-NH2 90% (240 µmol amine groups, 1 eq) was dissolved in 1 mL solution of sodium phosphate buffer (50 mM, 5 mM EDTA, pH 7.4). 0.26 mL of (1.6 mg/mL in the same buffer) solution of 2-4 iminothiolane (0.42 mg, 3.0 µmol, 1.4 eq) was added to dPG-NH2 90% and stirred for 20 min.
Afterwards, 2.45 mg (3 µmol, 1.4 eq) Mal-IDCC dye in 0.6 mL of the same buffer solution was added to the reaction mixture and stirred for 2 h. The mixture was taken and loaded on Sephadex G-25 superfine column for purification using PB 10 mM. Purification step was repeated three times to separate the free dyes form the conjugates. The resulting fractions were collected and desalted by frequent addition of nanopure water followed by centrifugation (3 x cycles, 6000 rpm, 10 min) using centrifugal filters (MWCO 3 kDa). The blue solutions were collected and lyophilized at -60°C for 24 h to yield a blue powder. The coupling of the dye to dPG-NH2 90% was analyzed on reverse phase thin layer chromatography (TLC).
Coupling of Fluorecein isothiocynate (FITC) to dPG-NH2 90%: dPG-NH2 90% (240 µmol amine groups, 1 eq) was disolved in 4 mL PBS (10 mM, pH 7.4). Then 0.8 mg (2 µmol) FITC was dissolved in 300 µL DMSO and added dropwise to dPG-NH2 90% solution. The resulting orange mixture was stirred for about 2 hours at room temperature, protected from light. Coupling of the dye to dPG-NH2 90% was checked using TLC. Mixture was transferred into a dialysis tube (4-6 kDa MW cutoff) and dialyzed against miliQ water for 24 hours in the dark. Concentration was controlled using filtering tubes and freeze-drying of dye solution aliquots.
Dynamic light scattering (DLS) and zeta potential determination were performed using a ZetaSizer Nano ZS instrument with an integrated 4 mW He-Ne laser (λ=633 nm; Malvern Instruments Ltd., Malvern, Worcestershire, UK). dPG-NH2-miR-34a polyplexes were prepared by dissolving 0.25 mg or 0.05 mg of dendrimer and the indicated molar ratio of miR34a in 1 mL DDW for the hydrodynamic radius measurement or the zeta potential measurement respectively. Samples were incubated for 20-30 minutes at room temperature, then PBS was added from X10 stock to a final buffer concentration of 15 mM, pH=7.4 to the zeta potential sample. All measurements were performed at 25°C using .Electrophoresis mobility shift assay (EMSA): The optimal ratio for the polyplex formation was studied by EMSA. In brief, 100 pmol of miR-34a was incubated with dPG-NH2 at 1:0.1, 1:0.2, 1:0.5, 1:1 and 1:2 molar ratios of carrier to miRNA (equivalent to N/P ratios of 0.4, 0.9, 2.5, 4.5 and 9) for 15 min at room temperature (RT). Mobility of free and nanocarriercomplexed miRNA was then analyzed by agarose gel electrophoresis. N/P ratios were calculated according to standard formulas reported in the literature [42] .
Cell culture: U-87 MG, T98G, U251, U373 and A172 human glioblastoma cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA).
Human umbilical vein endothelial cells (HUVEC) were purchased from Lonza, Switzerland.
Cancer cells were grown in DMEM supplemented with 10% FBS, 100 mg/mL Penicillin, 100 U/mL Streptomycin, 12.5 U/mL Nystatin, and 2 mM L-glutamine (Biological Industries, Bet Ha Emek, Israel). HUVEC were cultured in EGM-2 medium (Lonza, Switzerland). All cells were grown at 37°C in 5% CO2. or serum-free media were added to the lower chamber. Cells were allowed to migrate to the lower chamber for additional 4 h, followed by fixation using methanol and staining (Hema 3 stain system, Fisher HealthCare). The stained migrated cells were imaged using a Nikon TE2000E inverted microscope integrated with Nikon DS5 cooled CCD camera Migrated cells from the captured images were counted using NIH imageJ software. Migration was normalized to untreated cells towards 10% FBS.
HUVEC migration assay: Cells migration was evaluated using transwells chambers with pore size of 8 mm (Costar Corp., Corning, NY, USA). HUVEC (2x10 5 cells) were added to the upper chamber of 10 g/mL fibronectin-coated 24-well transwells chambers. Following 2 hours of incubation, conditioned media from A172 cells (pretreated with dPG-NH2-miR-34a, dPG-NH2-NC-miR or no treatment), serum-free media (negative control) or 10% FBS-8 containing media (positive control) were added to the lower chamber. Cells were allowed to migrate to the lower chamber for an additional 4 h, followed by fixation using methanol and staining (Hema 3 stain system, Fisher HealthCare). The stained migrated cells were imaged using a Nikon TE2000E inverted microscope integrated with Nikon DS5 cooled CCD camera.
Migrated cells from the captured images were counted using NIH ImageJ software.
Conditioned media preparation: Conditioned media (CM) for HUVEC migration assay was collected from confluent 100 mm tissue culture plates of A172 GBM cells following 48 hours incubation following treatment with dPG-NH2-miR-34a, dPG-NH2-NC-miR, or no treatment. Prior to the experiments, CM was filtered through 0.45 mm syringe filter to remove cells and debris.
Peripheral blood mononuclear cells (PBMCs) isolation: Blood sample obtained from healthy human donors was purchased from the blood bank of Sheba Medical Center (Ramat
